ANVISA grants marketing approval to Zylox-Tonbridge’s dilatation catheter

The company anticipates using ZENFlow Tiger in treating Budd-Chiari syndrome, and iliac vein compression syndrome.

August 31 2023

Brazilian Health Regulatory Agency ANVISA has granted marketing approval to Zylox-Tonbridge Medical Technology's ZENFlow Tiger LD PTA Dilatation Catheter (ZENFlow Tiger).

With this approval, the company intends to launch the product in the South American market.

ZENFlow Tiger features a tapered tip and short shoulder that enables easier access through complex lesions thereby facilitating in protecting normal blood vessels.

Its coaxial catheter shaft design also allows for rapid inflation and deflation. It is available in various sizes for use in different clinical needs.

The low-temperature molding technology ensures non-compliance while the braided delivery shaft provides pushability and kink resistance.

The company also anticipates using ZENFlow Tiger in treating Budd-Chiari syndrome, iliac vein compression syndrome, and other peripheral vascular occlusions.

It also expects better treatment efficacy of the product, when properly used along with mechanical thrombectomy devices and peripheral stents.

This April, Zylox-Tonbridge formed a strategic alliance with Guangdong Hicicare Science to facilitate the commercialisation of vascular guidewire products, under a co-branded label in China.

The partnership’s aim is to bring new neuro and peripheral-vascular interventional devices to Chinese physicians and patients.

The company generated a revenue of 6.23m yuan ($0.85m), representing a YoY increase of 128.7% during the first half of this year.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close